Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1620P - COVID-19 vaccines and cancer: Tailored information for Australia’s diverse populations

Date

16 Sep 2021

Session

ePoster Display

Topics

COVID-19 and Cancer

Tumour Site

Presenters

Vivienne Milch

Citation

Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713

Authors

V. Milch1, C. Der Vartanian2, M. Austen2, R. Wang2, C. Anderiesz3, D. Keefe4

Author affiliations

  • 1 Medical Director, Cancer Australia, 2010 - Surry Hills/AU
  • 2 National Cancer Control, Cancer Australia, 2010 - Surry Hills/AU
  • 3 Deputy Chief Executive Officer, Cancer Australia, 2010 - Surry Hills/AU
  • 4 Chief Executive Officer, Cancer Australia, 2010 - Surry Hills/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1620P

Background

As the COVID-19 vaccine rollout commenced in Australia in early 2021, limited evidence was available internationally about the safety and efficacy of the COVID-19 vaccines for people with cancer, particularly because cancer patients were largely excluded from the initial clinical trials. As such, people with cancer had many questions about the COVID-19 vaccines. Australia’s Indigenous and culturally and linguistically diverse (CALD) populations experience poorer cancer outcomes and have specific information needs. As the national cancer control agency, Cancer Australia has a leadership role in providing information to support optimal outcomes for people with cancer, including Australia’s Indigenous and CALD populations.

Methods

To understand and address the information needs about COVID-19 vaccines for people with cancer, Cancer Australia undertook a scoping review of national and international published literature and guidance, and sought input from key cancer control experts and consumers. In collaboration with Indigenous health and multicultural communications experts, Cancer Australia developed tailored information for Indigenous Australians and CALD populations affected by cancer.

Results

Cancer Australia developed a range of information resources relating to the COVID-19 vaccines and cancer, including Frequently Asked Questions (FAQs), and multimedia promotional collateral including animation and radio advertisements. The FAQs were adapted to provide culturally appropriate messaging for Indigenous Australians with cancer and translated into the ten most spoken languages in Australia. Multi-channel social media communication promoted uptake of the resources to CALD and Indigenous communities, and between March and May 2021, the social media campaign received over 800,000 impressions and the FAQs approximately 20,000 page views.

Conclusions

Throughout the pandemic, Cancer Australia has been responsive to the unique needs of the Australian cancer community. The development and dissemination of tailored information about COVID-19 vaccines for Indigenous and CALD populations is one example of how Cancer Australia aims to improve outcomes for all people with cancer in Australia.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.